Human Platelet Lysate Market, By Type (Heparin - Based Human Platelet Lysate and Heparin - Free Human Platelet Lysate ), By Application ( Clinical use and Research use), By End User (Biopharmaceutical Companies, Contract Research Organizations, and Others

Human Platelet Lysate Market, By Type (Heparin - Based Human Platelet Lysate and Heparin - Free Human Platelet Lysate ), By Application ( Clinical use and Research use), By End User (Biopharmaceutical Companies, Contract Research Organizations, and Others), And by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

A growth factor-rich cell culture supplement called human platelet lysate is made from healthy donor human platelets at blood facilities that are approved by both the U.S. Food and Drug Administration (FDA) and Health Canada. To reduce lot-to-lot variability, several donor units are pooled together during the production process. To prevent coagulation, an anticoagulant must be added. A supplement for cell culture growth made from human platelets is called human platelet lysate (HPL). By removing xenogeneic concerns and the spread of bovine prions, replacing foetal bovine serum (FBS) with HPL enables the increase and possible clinical grade production of stem cells. The human platelet lysate supplements for cell culture offer great cell performance and repeatable results. They are standardized and safe. Numerous experimental and clinical research projects have benefited from the development of human platelet lysates. Functional capacities are unaffected by human platelet lysates. Human blood-derived substances such as plasma, serum, umbilical cord blood serum, and platelet derivatives such platelet lysates can be used instead of FBS. Human platelet lysates have several uses, including biotechnology and pharmaceutical medication breakthrough therapy research, development, and production.

Market Dynamics

Increasing adoption of inorganic strategies by key players in market such as acquisitions is expected to drive market growth over the forecast period. For instance, in August 2021, BioLife Solutions, a biotechnology company, announced the acquisition of sexton biotechnologies, a biotechnology company, to expand cell and gene therapy tools portfolio. Sexton's bio production tools portfolio includes proprietary closed vials for cell therapy final dose packaging, human platelet lysate (HPL) media, a bio-defined replacement for fetal bovine serum or human serum used in cell manufacturing, and automated cell processing machines.

Key features of the study:

• This report provides in-depth analysis of the global human platelet lysate market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global human platelet lysate market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include STEMCELL Technologies Inc., Merck KGaA, Mill Creek Life Sciences, Merck & Co., Inc, AventaCell BioMedical, Compass Biomedical, Inc, Macopharma SA, Trinova Biochem GmbH, PL BioScience GmbH, Cook Regentec, Life Science Group Ltd., BBI Solutions, Regenexx, Thermo Fisher Scientific.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global human platelet lysate market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human platelet lysate market

Detailed Segmentation:

• Global Human Platelet Lysate Market, By Type:
• Heparin - Based Human Platelet Lysate
• Heparin - Free Human Platelet Lysate
• Global Human Platelet Lysate Market, By Application:
• Clinical Use
• Research Use
• Global Human Platelet Lysate Market, By End User:
• Biopharmaceutical Companies
• Contract Research Organizations
• Others
• Global Human Platelet Lysate Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region/Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• STEMCELL Technologies Inc
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Merck KGaA
• Mill Creek Life Sciences
• Merck & Co., Inc
• AventaCell BioMedical
• Compass Biomedical, Inc
• Macopharma SA
• Trinova Biochem GmbH
• PL BioScience GmbH
• Cook Regentec
• Life Science Group Ltd.
• BBI Solutions
• Regenexx
• Thermo Fisher Scientific

“*” marked represents similar segmentation in other categories in the respective section.